[Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)]

An Pediatr (Barc). 2014 Nov;81(5):303-9. doi: 10.1016/j.anpedi.2013.11.031. Epub 2014 Feb 26.
[Article in Spanish]

Abstract

Introduction: In 2009, two cases of seizures in adolescents following quadrivalent human papillomavirus vaccine (qHPV) administration, generated important media attention, and adversely affected public trust in this vaccine. Our objectives were to describe suspected adverse reactions (SARs) reported to the Pharmacovigilance Centre in the Valencian Community (PCVC) after administration of HPV vaccine, and to compare reporting rates of syncope and seizures following this vaccine with those of other vaccines administered to girls aged 13-15 years.

Material and methods: Descriptive study of SARs reported following this vaccine to the PCVC between 2007 and 2011.

Results: The clinical symptoms most frequently reported were dizziness, headache, and syncope. Reporting rates of syncope or loss of consciousness and seizures with qHPV vaccine were 17 and 3.2 per 100,000 doses administered, respectively, and 15 and 1.6 for syncope or loss of consciousness and syncopal seizures occurred on the day of vaccination. The reporting rates of syncope or loss of consciousness and seizures were 6.4 and 0.4, for the other vaccines.

Conclusions: Consistent with the media attention generated, and with results from other studies, the reporting rates of syncope or loss of consciousness and seizures were higher for the HPV vaccine than for other vaccines given in adolescence. Nevertheless, the overall information obtained on SARs following the qHPV vaccine suggests a good safety profile.

Keywords: Adverse reactions; Farmacovigilancia; Human papillomavirus; Pharmacovigilance; Reacción adversa; Reporting rate; Tasa de notificación; Vaccine; Vacuna; Virus del papiloma humano.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Female
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / adverse effects*
  • Humans
  • Pharmacovigilance*
  • Retrospective Studies
  • Seizures / epidemiology
  • Seizures / etiology
  • Spain
  • Syncope / epidemiology
  • Syncope / etiology
  • Time Factors

Substances

  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18